Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9
2 other identifiers
interventional
60
1 country
1
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Mar 1997
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 1997
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 1999
CompletedFirst Submitted
Initial submission to the registry
September 20, 1999
CompletedFirst Posted
Study publicly available on registry
September 21, 1999
CompletedJanuary 12, 2017
November 1, 2016
September 20, 1999
January 11, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Side effects
Drug use
Psychiatric symptoms
Cocaine craving
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (1)
New York State Psychiatric Institute
New York, New York, 10032, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Herbert Kleber, M.D.
New York State Psychiatric Institute
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
September 20, 1999
First Posted
September 21, 1999
Study Start
March 1, 1997
Study Completion
May 1, 1999
Last Updated
January 12, 2017
Record last verified: 2016-11